Epilepsy is a major brain disorder that affects over 50 million people worldwide. Nearly 30 percent of patients suffer from intractable epilepsy which is not controlled by conventional drugs. The beginning of SoVarGen came from research by professor Jeong Ho lee, KAIST, who was the first to identify the causes of intractable epilepsies. Professor Lee also serves as CTO of SoVarGen. Professor Lee approaches to the various neurological disorders from brain somatic mutation point of view. He also set up the patented mouse models for malignant brain disorders derived from human genes for the first time in the world. This new approach by molecular genetics diagnosis explains that the exact target underlying diseases and based on this validated target, SoVarGen is dedicated to developing novel diagnostics and breakthrough therapies for incurable brain disorder. With our core values, which are Sincerity, Values for Patients and Global Standard, we promise to contribute to patients' health and happiness. SoVarGen President & CEO Byung Tae Kim
| Website | http://www.sovargen.com |
| Revenue | $1 million |
| Employees | 1 (1 on RocketReach) |
| Founded | 2018 |
| Phone | +82 42-861-4292 |
| Fax | +82 70-8610-0150 |
| Industry | Manufacturing General, Drug Delivery, Manufacturing |
| Competitors | BASF, ADM, DuPont, Evonik, Corbion, Novozymes, Amyris, Geno, Zymergen, Inc. +27 more (view full list) |
| SIC | SIC Code 28 Companies, SIC Code 80 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular SoVarGen employee's phone or email?
SoVarGen Questions
The SoVarGen annual revenue was $1 million in 2026.
1 people are employed at SoVarGen.
The NAICS codes for SoVarGen are [3254, 325, 32].
The SIC codes for SoVarGen are [28, 80, 283].
